SRC and ovarian cancer: These results support the theory that paclitaxel treatment of ovarian cancer cells provokes an escalation of CSC-like resistant progenies in residual ovarian tumour populations, which hypothetically may use the activated Src pathway to evade cytotoxic effects of the chemotherapy.